Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 143 | 27 | 116 |
| Samples | 140 | 27 | 113 |
| Peptides | 85 | 15 | 75 |
Function
IL17A · Interleukin 17A
This gene is a member of the IL-17 receptor family which includes five members (IL-17RA-E) and the encoded protein is a proinflammatory cytokine produced by activated T cells. IL-17A-mediated downstream pathways induce the production of inflammatory molecules, chemokines, antimicrobial peptides, and remodeling proteins. The encoded protein elicits crucial impacts on host defense, cell trafficking, immune modulation, and tissue repair, with a key role in the induction of innate immune defenses. This cytokine stimulates non-hematopoietic cells and promotes chemokine production thereby attracting myeloid cells to inflammatory sites. This cytokine also regulates the activities of NF-kappaB and mitogen-activated protein kinases and can stimulate the expression of IL6 and cyclooxygenase-2 (PTGS2/COX-2), as well as enhance the production of nitric oxide (NO). IL-17A plays a pivotal role in various infectious diseases, inflammatory and autoimmune disorders, and cancer. High levels of this cytokine are associated with several chronic inflammatory diseases including rheumatoid arthritis, psoriasis and multiple sclerosis. The lung damage induced by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is to a large extent, a result of the inflammatory response promoted by cytokines such as IL17A. [provided by RefSeq, Sep 2020].
Isoforms & Proteins
1 transcript · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000648244 | Q16552 | 143 | 85 |
Gene Properties
Recurrent Mutations
All 85 amino-acid changes on canonical ENST00000648244 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in IL17A · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in IL17A – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Acute Myeloid Leukemia | 2/90 2% | 0/0 0% |
| Melanoma | 3/210 1% | 30/1899 2% |
| Non-Small Cell Lung Carcinoma | 8/304 3% | 11/1390 1% |
| Osteosarcoma | 2/45 4% | 0/166 0% |
| Endometrial Carcinoma | 1/42 2% | 5/612 1% |
| Squamous Cell Lung Carcinoma | 1/57 2% | 5/810 1% |
| Germ Cell Tumour | 0/25 0% | 1/169 1% |
| Colorectal Carcinoma | 4/143 3% | 12/3239 0% |
| Neuroendocrine Tumour | 3/154 2% | 0/577 0% |
| Small Cell Lung Carcinoma | 0/9 0% | 3/752 0% |
| Other Sarcomas | 0/69 0% | 3/699 0% |
| Other Solid Cancers | 0/94 0% | 6/1515 0% |
| Ewings Sarcoma | 1/63 2% | 0/262 0% |
| Head and Neck Carcinoma | 0/85 0% | 5/1574 0% |
| Bladder Carcinoma | 0/58 0% | 3/956 0% |
| Ovarian Carcinoma | 0/109 0% | 3/998 0% |
| Cervical Carcinoma | 0/35 0% | 1/422 0% |
| Non-Cancerous | 0/104 0% | 2/830 0% |
| Hepatocellular Carcinoma | 0/46 0% | 4/2210 0% |
| Glioma | 0/52 0% | 4/2127 0% |
| Prostate Carcinoma | 0/13 0% | 3/2105 0% |
| Breast Carcinoma | 2/144 1% | 2/3264 0% |
| Thyroid Gland Carcinoma | 0/45 0% | 2/1592 0% |
| Gastric Carcinoma | 0/74 0% | 2/1809 0% |
| Biliary Tract Carcinoma | 0/54 0% | 1/950 0% |
| Other Blood Cancers | 0/61 0% | 2/2725 0% |
| Pancreatic Carcinoma | 0/89 0% | 1/1611 0% |
| Kidney Carcinoma | 0/85 0% | 1/1862 0% |
| B-Cell Non-Hodgkins Lymphoma | 0/88 0% | 1/2534 0% |
Mutation Distribution
Where IL17A is mutated · all tissues, split by cell line vs tissue
How many mutations in IL17A were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 1 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 143 mutations in IL17A
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|